Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.50 |
| ▸ | JAK3 | P52333 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | CAMK1D | Q8IU85 | 11/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | RIPK4 | P57078 | 1/20 | 0.47 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.47 |
| ▸ | CAMK1 | Q14012 | 1/20 | 0.47 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.47 |
| ▸ | PNCK | Q6P2M8 | 1/20 | 0.47 |
| ▸ | CAMK1G | Q96NX5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894549 | 1.00 | BTK (0.56) | BTKKCNH2JAK3EGFRLCK | |
| SCHEMBL10168712 | 0.91 | BTK (0.50) | BTKKCNH2JAK3EGFRLCK | |
| SCHEMBL894691 | 0.88 | BTK (0.55) | BTKKCNH2JAK3EGFRLCK | |
| SCHEMBL893994 | 0.84 | JAK3 (0.59) | BTKKCNH2JAK3EGFRLCK | |
| SCHEMBL893993 | 0.84 | JAK3 (0.59) | BTKKCNH2JAK3EGFRLCK | |
| SCHEMBL27851733 | 0.83 | JAK3 (0.51) | BTKKCNH2JAK3EGFRLCK | |
| SCHEMBL895137 | 0.80 | BTK (0.61) | BTKKCNH2JAK3EGFRLCK | |
| SCHEMBL893925 | 0.79 | BTK (0.47) | BTKKCNH2JAK3EGFRLCK | |
| SCHEMBL893923 | 0.79 | BTK (0.47) | BTKKCNH2JAK3EGFRLCK | |
| SCHEMBL894314 | 0.78 | BTK (0.90) | BTKCAMK1DSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440204-B1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2440204-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | Bristol-Myers Squibb Company (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
| WO-2010144647-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | BTK 2/4885KCNH2 3180/4885JAK3 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.